EXACT Sciences News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

04.10.24	FDA Approves Exact Sciences' Colorectal Cancer Screening Test Cologuard Plus (RTTNews)
15.04.24	Exact Sciences Appoints Aaron Bloomer As Chief Financial Officer (RTTNews)
08.01.24	Exact Sciences Sees Q4 Revenue Above View; CFO Jeff Elliott To Step Down (RTTNews)
07.12.23	Exact Sciences Awards Grants to 23 Organizations Focused on Increasing Colorectal Cancer Screenings (PR Newswire)
30.11.23	Exact Sciences Presents Multiple Studies at San Antonio Breast Cancer Symposium Supporting Optimization and Individualization of Therapy for Breast Cancer Patients (PR Newswire)
17.11.23	Exact Sciences Files Lawsuit Against Geneoscopy For Infringing Patented Technology (RTTNews)
17.11.23	Exact Sciences Files Patent Infringement Lawsuit Against Geneoscopy (PR Newswire)
22.10.23	Next-Generation Cologuard® Test Demonstrates High Sensitivity and Specificity in Pivotal BLUE-C Study, Significantly Outperforming Fecal Immunochemical Testing (FIT) for Cancer and Precancer Detection (PR Newswire)
21.10.23	Exact Sciences Advances Early Cancer Detection and Precision Oncology Programs with Data Presentations at ESMO 2023 Annual Congress (PR Newswire)
09.10.23	Exact Sciences to Present Late-Breaking Data from Pivotal BLUE-C Study on Next-Generation Cologuard at ACG 2023 (PR Newswire)
12.09.23	Agilent To Sell Resolution Bioscience To Exact Sciences For Undisclosed Sum (RTTNews)
30.08.23	Exact Sciences Lab and OncoExTra Test Selected by National Cancer Institute for ComboMATCH Clinical Trials (PR Newswire)
21.08.23	Not a Wall, But an Obstacle Course: New Findings Reveal Why 45-Year-Olds Are Avoiding Colorectal Cancer Screenings (PR Newswire)
21.06.23	Pre-market Movers: VCIG, DTI, PCT, KWE, AULT… (RTTNews)
21.06.23	Exact Sciences: Next-gen Cologuard Meets All Endpoints In Pivotal BLUE-C Study (RTTNews)
20.06.23	Next-generation Cologuard Test Demonstrates 94 Percent Sensitivity for Colorectal Cancer at 91 Percent Specificity, Raising the Bar in Non-invasive Screening (PR Newswire)
01.06.23	EXACT SCIENCES EARNS 2023 GREAT PLACE TO WORK® CERTIFICATION™ (PR Newswire)
26.05.23	Exact Sciences Presents New Long-Term Patient Outcomes in Multi-Cancer Early Detection and Breast Cancer Recurrence Testing at ASCO® 2023 (PR Newswire)
17.05.23	EXACT SCIENCES AWARDS GRANTS TO 18 ORGANIZATIONS FOCUSED ON INCREASING COLORECTAL CANCER SCREENINGS (PR Newswire)
10.05.23	Pre-market Movers: CTIC, UPST, ISIG, SFWL, CUEN… (RTTNews)
09.05.23	Exact Sciences Extends Leadership in Colorectal Cancer Screening with New Data Presented at Digestive Disease Week® Annual Meeting (PR Newswire)
12.04.23	Exact Sciences Presents Advancements in Cancer Detection at American Association for Cancer Research® 2023 Annual Meeting (PR Newswire)
07.02.23	Exact Sciences Launches OncoExTra™ Cancer Therapy Selection Test in the U.S. (PR Newswire)
20.12.22	Medicare and Insurance Policy Updates in 2023 Will Improve Cancer Screening Access by Removing Patient Colonoscopy Cost Following a Positive Cologuard Test (PR Newswire)
09.12.22	Exact Sciences Presents First Time Data Detailing Ability to Predict Radiation Therapy Benefit in Breast Cancer Patients (PR Newswire)
06.12.22	Exact Sciences Highlights the Impact of Precision Oncology Portfolio on Breast Cancer Treatment with 10 New Data Presentations at SABCS® 2022 (PR Newswire)
24.10.22	Exact Sciences Expands Leadership in Colorectal Cancer Screening with New Data Presented at the American College of Gastroenterology 2022 Annual Meeting (PR Newswire)
10.09.22	Exact Sciences Demonstrates Power of Multi-Cancer Early Detection Approach with Data Presentation at the 2022 European Society for Medical Oncology Congress (PR Newswire)
03.08.22	ATRC Sees 18-21% Revenue Growth, EVH Q2 Results Beat Estimates, EXAS Trims Outlook, HRMY On Watch... (RTTNews)
02.08.22	Exact Sciences and West German Study Group Announce New Study to Validate Detection of Minimal Residual Disease in Early-Stage Breast Cancer Patients (PR Newswire)
08.07.22	Exact Sciences Applauds Proposed CMS Change to Colorectal Cancer Screening Policy (PR Newswire)
21.06.22	Ultima Genomics, Exact Sciences In Deal To Improve Patient Access To Genomics-based Testing (RTTNews)
21.06.22	Ultima Genomics and Exact Sciences enter long-term supply agreement aimed at improving patient access to genomic testing by driving down sequencing costs (PR Newswire)
27.05.22	Exact Sciences Showcases Breadth of Early Detection and Treatment Guidance Portfolio with Multiple Data Presentations at ASCO 2022 (PR Newswire)
28.04.22	Updated ASCO Guidelines Strongly Recommend Use of the Oncotype DX Breast Recurrence Score® Test in Node-Negative and the Majority of Node-Positive Early-Stage Breast Cancer Patients (PR Newswire)
27.04.22	AMAM Awaits ACE-Breast-02 Study Data, CNC Posts Strong Q1 Results, EXAS Boosts Outlook (RTTNews)
07.03.22	Katie Couric and Cologuard Team Up to Spread Awareness and Urgency for People to Get Screened for Colon Cancer (PR Newswire)
18.01.22	Exact Sciences Presents Data Showing Improved Accuracy of Second-generation Cologuard® Test and Progress Toward an Even Better Colorectal Cancer Screening Solution for Patients (PR Newswire)
10.01.22	Exact Sciences Buys PreventionGenetics For $190 Mln; Sees Financial, Corporate Growth In 2022 (RTTNews)
10.12.21	Pre-market Movers: EFOI, EVBG, CNTX, AI, AOUT… (RTTNews)
08.12.21	New Data Presented at SABCS® 2021 Strengthen Value of Oncotype DX Breast Recurrence Score® Test to Inform Clinical Decision-making (PR Newswire)
01.12.21	Publication in The New England Journal of Medicine Confirms that Tens of Thousands of Women with Node-positive, Early-stage Breast Cancer Can Avoid Chemotherapy with the Oncotype DX® Test (PR Newswire)
23.11.21	New 20-Year Data Published in Urologic Oncology Validates Adverse Pathology as Predictor of Prostate Cancer Outcomes in Clinically Low-Risk Patients (PR Newswire)
18.11.21	Exact Sciences and Jefferson Health Commence Collaboration on Multi-Cancer Earlier Detection (PR Newswire)
04.11.21	Section 32 Raises $740 Million Venture Fund (PR Newswire)
25.10.21	New Cologuard® Modeling Data Show Patient Navigation Matters When Reaching Underserved Populations for Colorectal Cancer (CRC) Screening (PR Newswire)
16.08.21	Exact Sciences receives regulatory approval for the Oncotype DX Breast Recurrence Score® Program in Japan (PR Newswire)
13.08.21	Clinical Gastroenterology and Hepatology Publishes Data Showing Exact Sciences' Oncoguard™ Liver Liquid Biopsy Test Delivers Enhanced Performance for Early-stage Detection of Hepatocellular Carcinoma (PR Newswire)
28.07.21	Exact Sciences Announces Second Quarter 2021 Results (PR Newswire)
08.07.21	Exact Sciences schedules second quarter 2021 earnings call (PR Newswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Roche Hldg G	255.50	0.75 %	K V
Nestle	74.88	0.62 %	K V
CieFinRichemont	137.90	0.40 %	K V
Swiss Life Hldg	699.60	0.32 %	K V
Swisscom	504.50	0.30 %	K V
Sika	215.80	-0.37 %	K V
Givaudan	3’966.00	-0.40 %	K V
Lonza Grp	535.80	-0.41 %	K V
Geberit	514.60	-0.46 %	K V
ABB	49.07	-0.95 %	K V

mehr

26.11.24		Gute Stimmung in New York: Börsianer lassen NASDAQ Composite schlussendlich steigen
26.11.24		Starker Wochentag in New York: NASDAQ Composite präsentiert sich nachmittags fester
26.11.24		Pluszeichen in New York: NASDAQ Composite mittags in Grün
26.11.24		Aufschläge in New York: Zum Handelsstart Pluszeichen im NASDAQ Composite
19.11.24		Pluszeichen in New York: NASDAQ Composite steigt zum Handelsende
19.11.24		NASDAQ-Handel: So performt der NASDAQ Composite am Nachmittag
06.11.24		Gewinne in New York: NASDAQ Composite zum Ende des Mittwochshandels mit positivem Vorzeichen
06.11.24		Aufschläge in New York: NASDAQ Composite verbucht am Mittwochnachmittag Gewinne